Dr. McCollum on Treatment in the First-Line Setting for CRC

A. David McCollum, MD
Published: Thursday, Nov 16, 2017



A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

According to McCollum, there was a burst of activity in the early part of this millennia with the approval of many agents. It was discovered that there were some molecular predictors to optimize regimens for particular forms of CRC.

RAS, BRAF, and HER2 testing might specify certain regimens for patients. Additionally, the sidedness of the tumor may predict which treatment will be successful, explains McCollum.
 


A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

According to McCollum, there was a burst of activity in the early part of this millennia with the approval of many agents. It was discovered that there were some molecular predictors to optimize regimens for particular forms of CRC.

RAS, BRAF, and HER2 testing might specify certain regimens for patients. Additionally, the sidedness of the tumor may predict which treatment will be successful, explains McCollum.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x